{
    "clinical_study": {
        "@rank": "53588", 
        "arm_group": [
            {
                "arm_group_label": "Cabazitaxel", 
                "arm_group_type": "Experimental", 
                "description": "Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion"
            }, 
            {
                "arm_group_label": "Vinflunine", 
                "arm_group_type": "Active Comparator", 
                "description": "\u2022 Vinflunine will be given intravenously once every 21 days, starting at a dose of:\n320 mg/m2 in patients aged \u226475 years with PS 0 and no prior pelvic radiation\n280 mg/m2 in patients aged >75 - \u226480 years, and/or with PS 1 and/or prior pelvic radiation,\n250 mg/m2 in patients aged >80 years."
            }
        ], 
        "brief_summary": {
            "textblock": "Due to limited experience with cabazitaxel in TCCU, the study will be started as a\n      randomised phase II study. The aim of the phase II study is to evaluate if the response\n      rates (CR + PR) are sufficiently high to further study the treatment regimens in a phase III\n      setting."
        }, 
        "brief_title": "Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Urothelium Transitional Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Transitional Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Once it is confirmed that the subjects fulfil the eligibility criteria and have signed the\n      informed consent, they will be randomised to receive treatment based on cabazitaxel or\n      vinflunine according to the following study schema:\n\n      (Randomize 1:1)\n\n        -  Cabazitaxel 25 mg/m2 q3w\n\n        -  Vinflunine 250-320 mg/m2 q3w\n\n      Random assignment of treatment will be stratified by the presence of 0 versus 1 of the\n      following unfavourable prognostic risk factors proposed recently by Bellmunt et al. (1):\n\n        -  Eastern Cooperative Oncology Group (ECOG) PS 1.\n\n        -  Anaemia with Hb <10 g/dL.\n\n        -  Presence of liver metastases.\n\n      All patients enrolled in the study will receive a cycle of treatment with the study\n      medication (cabazitaxel or vinflunine) every 21 days until disease progression or\n      intolerable/unacceptable toxicity. Tumour evaluations will be scheduled every 6 weeks until\n      progression"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Histologically confirmed TCCU (urinary bladder, urethra, ureter or renal pelvis).\n             Patients with mixed histology may be enrolled if TCCU is the predominant component\n             (i.e., > 50% of the histopathology sample) with the exception of neuroendocrine or\n             small cell carcinoma.\n\n          -  Advanced disease defined as a locally advanced tumour considered unresectable (T4b),\n             node involvement in the inguinal area or above the aortic bifurcation (that are\n             considered to be distant nodes and so metastasis) or metastasis in distant organs.\n\n          -  Patient should have received one prior platinum-based chemotherapy treatment for\n             locally advanced or stage IV TCCU. Prior platinum-based adjuvant or neoadjuvant\n             therapy is allowed if more than 6 months have elapsed since the end of adjuvant or\n             neoadjuvant therapy till tumour relapse.\n\n          -  At least one measurable tumour lesion (measurable disease, as defined by the Response\n             Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1\n\n          -  \u226518 years.\n\n          -  ECOG PS  0 or 1.\n\n          -  May have no more than ONE of the following unfavourable risk factors:\n\n               1. haemoglobin <10 g/dL\n\n               2. presence of liver metastasis\n\n               3. ECOG PS 1\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Adequate hematologic, hepatic, and renal function, defined by:\n\n          -  Females of childbearing potential must have a negative serum pregnancy test within 7\n             days of study entry.\n\n        Exclusion Criteria:\n\n          -  Patients that have 2 or more of the following unfavourable risk factors:\n\n               1. Haemoglobin <10 g/L\n\n               2. Liver metastasis\n\n               3. ECOG PS 1.\n\n          -  Women who are currently pregnant or breast-feeding.\n\n          -  Any unresolved non-hematologic Adverse Event (AE) grade >1 (Common Toxicity Criteria\n             for Adverse Effects (NCI-CTCAE) Version  4.0) from previous anti-cancer therapy\n             (other than alopecia)\n\n          -  Patients who had undergone major surgery, radiation therapy or treatment with\n             chemotherapy or any investigational agent within 28 days prior to Study day 1.\n\n          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition\n\n          -  History of another neoplasm.\n\n          -  History of hypersensitivity reactions to taxanes (docetaxel) (cabazitaxel specific\n             criteria), vinca alkaloids (vinflunine specific criteria) or to any of the\n             formulation excipients, including polysorbate 80\n\n          -  clear evidence or symptoms of central nervous system metastasis (cabazitaxel specific\n             criteria).\n\n          -  Clinically significant cardiac condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "372", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830231", 
            "org_study_id": "Secavin-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cabazitaxel", 
                "description": "Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.", 
                "intervention_name": "Cabazitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Jevtana"
            }, 
            {
                "arm_group_label": "Vinflunine", 
                "description": "Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:\n320 mg/m2 in patients aged \u226475 years with PS 0 and no prior pelvic radiation, and of\n280 mg/m2 in patients aged >75 - \u226480 years or with PS 1 or prior pelvic radiation,\n250 mg/m2 in patients aged >80 years.", 
                "intervention_name": "Vinflunine", 
                "intervention_type": "Drug", 
                "other_name": "Javlor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vinblastine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TCCU", 
            "Vinflunine", 
            "Cabazitaxel", 
            "Metastatic", 
            "Locally advance"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "NKI-AvL"
                }, 
                "investigator": {
                    "last_name": "Martijn Kerst, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Vumc Amsterdam"
                }, 
                "investigator": {
                    "last_name": "van den Eertwegh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands"
                    }, 
                    "name": "St. Antoniusziekenhuis"
                }, 
                "investigator": {
                    "last_name": "Maartje Los, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Erasmus MC Rotterdam"
                }, 
                "investigator": {
                    "last_name": "Ronald De witt, MD, PHD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "state": "A Coru\u00f1a", 
                        "zip": "15706"
                    }, 
                    "name": "Hospital Cl\u00ednico Universitario de Santiago"
                }, 
                "investigator": {
                    "last_name": "Urbano Anido", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elche", 
                        "country": "Spain", 
                        "state": "Alicante", 
                        "zip": "03203"
                    }, 
                    "name": "Hospital General Universitario de Elche"
                }, 
                "investigator": {
                    "last_name": "Federico J. V\u00e1zquez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra", 
                        "zip": "31008"
                    }, 
                    "name": "Cl\u00ednica Universidad de Navarra"
                }, 
                "investigator": {
                    "last_name": "Jose L. P\u00e9rez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain", 
                        "zip": "15009"
                    }, 
                    "name": "Centro Oncologico de Galica"
                }, 
                "investigator": {
                    "last_name": "Ana Medina, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain", 
                        "zip": "15006"
                    }, 
                    "name": "Complejo Hospitalario Universitario A Coru\u00f1a"
                }, 
                "investigator": {
                    "last_name": "Luis Miguel Ant\u00f3n Aparicio, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "93 274 61 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Vall d\u00b4Hebron"
                }, 
                "investigator": {
                    "last_name": "Rafael Morales, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joaquim Bellmunt, MD/PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }, 
                    "name": "Hospital del Mar"
                }, 
                "investigator": {
                    "last_name": "Joaquim Bellmunt, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00e1ceres", 
                        "country": "Spain", 
                        "zip": "10003"
                    }, 
                    "name": "Hospital San Pedro de Alc\u00e1ntara"
                }, 
                "investigator": {
                    "last_name": "Ricardo Collado", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Ram\u00f3n y Cajal"
                }, 
                "investigator": {
                    "last_name": "Enrique Grande, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Cl\u00ednico San Carlos"
                }, 
                "investigator": {
                    "last_name": "Jos\u00e9 Luis Gonz\u00e1lez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Daniel Castellano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Fundaci\u00f3n Jim\u00e9nez D\u00edaz"
                }, 
                "investigator": {
                    "last_name": "Gustavo Rubio", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murcia", 
                        "country": "Spain", 
                        "zip": "30008"
                    }, 
                    "name": "Hospital Morales Meseguer"
                }, 
                "investigator": {
                    "last_name": "Enrique Gonz\u00e1lez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ourense", 
                        "country": "Spain", 
                        "zip": "32005"
                    }, 
                    "name": "Complejo Hospitalario Universitario Ourense. Hospital Santa Mar\u00eda Nai"
                }, 
                "investigator": {
                    "last_name": "Ovidio Fern\u00e1ndez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "zip": "07198"
                    }, 
                    "name": "Hospital Son Llatzer"
                }, 
                "investigator": {
                    "last_name": "Maria Bel\u00e9n Gonz\u00e1lez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Hospital Lzoano Blesa"
                }, 
                "investigator": {
                    "last_name": "Eduardo Pujol, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium", 
        "overall_contact": {
            "email": "jbellmunt@parcdesalutmar.cat", 
            "last_name": "Joaquim Bellmunt, MD/PhD", 
            "phone": "+34 93 2483137"
        }, 
        "overall_contact_backup": {
            "email": "oncologia.apro@gmail.com", 
            "last_name": "Inmaculada Must\u00e9", 
            "phone": "+34 93 2483137"
        }, 
        "overall_official": {
            "affiliation": "APRO", 
            "last_name": "Joaquim Bellmunt, MD/PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Efficacy of cabazitaxel compared to vinflunine on terms of improved objective response rate (ORR)", 
                "measure": "Phase II main objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objective response rate (ORR) of subjects with metastatic or locally advanced previously treated TCCU.", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization to disease progression or until 18 months from enrolment."
            }, 
            {
                "measure": "Phase III main objective: To assess the efficacy of cabazitaxel compared to vinflunine in terms of improved overall survival (OS)  of subjects with metastatic or locally advanced, previously treated TCCU.", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization to death from any cause or until 18 months from enrolment."
            }
        ], 
        "reference": {
            "citation": "Bellmunt JCT, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum containing regimens. J Clin Oncol 2010; 28: 1850-55"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830231"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Phase II secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved progression-free survival (PFS) and overall survival (OS).", 
                "safety_issue": "No", 
                "time_frame": "From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier)"
            }, 
            {
                "measure": "Phase II secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported.", 
                "safety_issue": "Yes", 
                "time_frame": "From the date the informed consent is signed up to 30 days after the last dose."
            }, 
            {
                "measure": "Phase III secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objetive response rate (ORR) and progression free survival (PFS).", 
                "safety_issue": "No", 
                "time_frame": "From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier)"
            }, 
            {
                "measure": "Phase III secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported.", 
                "safety_issue": "Yes", 
                "time_frame": "From the date the informed consent is signed up to 30 days after the last dose."
            }
        ], 
        "source": "Associaci\u00f3 per a la Recerca Oncologica, Spain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Associaci\u00f3 per a la Recerca Oncologica, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}